Cephalon Showcasing Treanda Use For Refractory Indolent NHL At ASH
Executive Summary
Cephalon's oncology drug Treanda is getting attention at the 2008 American Society of Hematology annual meeting, where the company is starting to showcase its use in the newest indication - refractory indolent non-Hodgkins lymphoma
You may also be interested in...
Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says
Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.
Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says
Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.
Cephalon Is Not Sleeping On Moving Patients From Provigil To Nuvigil
Cephalon's plans to protect its billion-dollar wakefulness franchise from the impact of generic competition to Provigil centers on switching patients to a second-generation drug, Nuvigil, with expanded indications